Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
Minerva Neurosciences (NASDAQ: NERV) will release its third-quarter 2020 financial results on November 2, 2020, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Neurosciences (NASDAQ: NERV) will release its third-quarter 2020 financial results on November 2, 2020, at 8:30 a.m. ET. The conference call will provide business updates and insights into their clinical-stage biopharmaceutical developments targeting central nervous system disorders. Key products in their portfolio include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. Investors can access the call by dialing the provided numbers and a webcast will be available for later viewing.
Positive
- Upcoming Q3 financial results announcement on November 2, 2020
- Potential for product portfolio growth with roluperidone and MIN-301
Negative
- None.
Details
News Market Reaction – NERV
The recorded move for NERV in the trading session of this news was -0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host conference call
WALTHAM, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2020 on Monday, November 2, 2020. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 (domestic) or (765) 507-2618 (international) and referring to conference ID number 9459728. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.